Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML.
Cell Death
/ drug effects
Cell Line, Tumor
Endoplasmic Reticulum Stress
/ drug effects
Gene Duplication
Humans
Leukemia, Myeloid, Acute
/ genetics
Oxidative Stress
/ drug effects
Tandem Repeat Sequences
Tretinoin
/ pharmacology
Unfolded Protein Response
/ drug effects
fms-Like Tyrosine Kinase 3
/ genetics
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
23 12 2019
23 12 2019
Historique:
received:
03
06
2019
accepted:
28
10
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
17
9
2020
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is often characterized by the expression of fusion or mutant proteins that cause impaired differentiation and enhanced proliferation and survival. The presence of mutant proteins prone to misfolding can render the cells sensitive to endoplasmic reticulum (ER) stress and oxidative stress that could otherwise be overcome. Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. Importantly, the combination of RA, Tm, and ATO decreased the colony-forming capacity of primary leukemic blasts bearing the FLT-ITD mutation without affecting healthy hematopoietic progenitor cells. We demonstrate in cell lines that combination of these drugs generates ER and oxidative stresses and impairs maturation and causes accumulation of FLT3 protein in the ER. Our data provide a proof of concept that low amounts of drugs that generate ER and oxidative stresses combined with RA could be an effective targeted therapy to hit AML cells characterized by MLL fusion proteins and FLT3-ITD mutation.
Identifiants
pubmed: 31834935
pii: 429646
doi: 10.1182/bloodadvances.2019000540
pmc: PMC6929380
doi:
Substances chimiques
Tretinoin
5688UTC01R
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4155-4160Informations de copyright
© 2019 by The American Society of Hematology.
Références
Int J Clin Exp Med. 2010 Jan 08;3(1):33-40
pubmed: 20369038
Antioxid Redox Signal. 2014 Jul 20;21(3):396-413
pubmed: 24702237
Leuk Lymphoma. 2017 Oct;58(10):2426-2438
pubmed: 28276286
Blood. 2014 Jul 10;124(2):263-72
pubmed: 24695851
Int J Hematol. 2013 Jun;97(6):683-94
pubmed: 23613268
Nat Cell Biol. 2013 May;15(5):481-90
pubmed: 23624402
Curr Opin Hematol. 2014 Mar;21(2):79-86
pubmed: 24419335
Oncotarget. 2017 Apr 18;8(16):26613-26624
pubmed: 28460451
Blood. 2016 Jun 9;127(23):2867-78
pubmed: 27103744
Blood Adv. 2017 Nov 14;1(24):2281-2294
pubmed: 29296877
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Br J Haematol. 2015 Jan;168(1):14-25
pubmed: 25296649
Mol Cell Biol. 2005 May;25(9):3690-703
pubmed: 15831474
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6669-E6678
pubmed: 27791036
Prion. 2014 Mar-Apr;8(2):null
pubmed: 24818993
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Blood. 2016 Feb 18;127(7):882-92
pubmed: 26286850
Blood Rev. 2015 Jul;29(4):263-8
pubmed: 25631637
Blood. 2010 Dec 9;116(24):5089-102
pubmed: 20705759
Leukemia. 2018 Feb;32(2):285-294
pubmed: 28776567
Leukemia. 2013 Nov;27(11):2165-76
pubmed: 23628958